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The ACAT Inhibitor CP-113,818
Markedly Reduces Amyloid Pathology
in a Mouse Model of Alzheimer’s Disease
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disor-
der that is characterized by progressive cognitive im-
pairment, personality changes, and specific neuropath-
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ological abnormalities. Senile (or amyloid) plaques,and Dora M. Kovacs2,3,4,*
extensive neuronal loss, and neurofibrillary tangles rep-1JSW-Research Forschungslabor GmbH
resent the main histological hallmarks observed in ADInstitute of Experimental Pharmacology
brains. Amyloid -peptide (A) aggregates form the coreRankengasse 28
of senile plaques and are increased in all forms of the8020 Graz
disease (Glenner and Wong, 1984). A consistent featureAustria
of familial AD mutations causing early-onset forms of2 Neurobiology of Disease Laboratory
the disease is an overproduction of A peptides or of3 Genetics and Aging Research Unit
the more pathogenic A42 in specific regions of the brain4 Department of Neurology/MassGeneral Institute
(Selkoe, 1999). A is a 39–43 amino acid hydrophobicfor Neurodegenerative Disease
polypeptide that is derived from a large precursor, the5 Department of Pathology
amyloid precursor protein (APP) (Kang et al., 1987; TanziMassachusetts General Hospital
et al., 1987). The enzymes that generate A have beenHarvard Medical School
identified and partially characterized. At the N terminus114 16th Street
of A, APP is cleaved by -secretase or -site APP-Charlestown, Massachusetts 02129
cleaving enzyme 1 (BACE1), while at the C terminus it6 Department of Neuroscience
is cleaved by a multisubunit aspartyl protease complex
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called -secretase (Aguzzi and Haass, 2003; Citron,
4500 San Pablo Road 2004; De Strooper, 2003; Sinha et al., 1999; Vassar, 2004;
Jacksonville, Florida 32224 Xia and Wolfe, 2003). Alternatively, -secretase cleaves
in the middle of the A region of APP, preventing A
generation (Ling et al., 2003). Following - and -secre-
tase cleavages, A is released from the membrane and
can then be degraded, bind specific proteins like
Summary 2-macroglobulin and ApoE, or aggregate into -pleated
fibrillar oligomers (Ling et al., 2003).
Amyloid -peptide (A) accumulation in specific brain Studies of both animal and cellular models of AD have
regions is a pathological hallmark of Alzheimer’s dis- shown that cholesterol homeostasis and distribution
ease (AD). We have previously reported that a well- regulate A generation. Genetic and epidemiological
characterized acyl-coenzyme A: cholesterol acyltrans- data support a role for altered cholesterol metabolism
ferase (ACAT) inhibitor, CP-113,818, inhibits A pro- in the pathogenesis of AD (Burns and Duff, 2002; Hart-
duction in cell-based experiments. Here, we assessed mann, 2001; Puglielli et al., 2003). Statins, which inhibit
the efficacy of CP-113,818 in reducing AD-like pathol- cholesterol generation and internalization and thereby
lower total cholesterol in cells, reduce A production inogy in the brains of transgenic mice expressing human
cells and in most animal models of AD (Petanceska etAPP751 containing the London (V717I) and Swedish
al., 2002). Retrospective and prospective clinical studies(K670M/N671L) mutations. Two months of treatment
suggest that statins may lower the risk of developingwith CP-113,818 reduced the accumulation of amyloid
AD, but large clinical trials are ongoing (Wolozin, 2004). Itplaques by 88%–99% and membrane/insoluble A lev-
remains to be shown that statins can provide significantels by 83%–96%, while also decreasing brain choles-
cognitive benefits for AD patients with normal serumteryl-esters by 86%. Additionally, soluble A42 was re-
cholesterol.duced by 34% in brain homogenates. Spatial learning
Multiple pathways are involved in regulation of cellularwas slightly improved and correlated with decreased
cholesterol distribution. One of these pathways is medi-A levels. In nontransgenic littermates, CP-113,818
ated by acyl-coenzyme A: cholesterol acyltransferasealso reduced ectodomain shedding of endogenous
(ACAT), an endoplasmic reticulum resident enzyme.APP in the brain. Our results suggest that ACAT inhibi-
ACAT regulates intracellular cholesterol homeostasis bytion may be effective in the prevention and treatment
converting membrane cholesterol into cytoplasmic cho-
of AD by inhibiting generation of the A peptide. lesteryl-ester droplets for storage, until free cholesterol
and fatty acids are needed for normal membrane and
cellular functions (Chang et al., 2001). ACAT inhibition
*Correspondence: dora_kovacs@hms.harvard.edu has long been studied as a potential antiatherosclerotic
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absorption and foam cell formation (Shah, 2003). Weand Gerontology, University of Wisconsin-Madison, Veterans Ad-
have previously presented genetic, metabolic, and phar-ministration Hospital (GRECC 11G), 2500 Overlook Terrace, Madi-
son, Wisconsin 53705. macological evidence that inhibition of ACAT activity
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results in reduced A generation in cell-based models ish (K670M/N671L) mutations under the regulatory con-
trol of the murine Thy-1 promoter (mThy1-hAPP751)of AD and in primary neurons (Puglielli et al., 2001). In
(Rockenstein et al., 2001). These animals develop de-particular, we showed that two ACAT inhibitors, CP-
tectable plaques in the neocortex and hippocampus at113,818 and Dup128, inhibited A production by up
the ages of 4 and 6 months, respectively, and showto 50%.
memory deficits starting at 6 months of age. Given ourHere, we used the ACAT inhibitor CP-113,818 in a
prior observations that CP-113,818 reduced A genera-transgenic mouse model of AD to assess whether ACAT
tion and not clearance, we used relatively young hAPPis a potential target for antiamyloid therapy in patients
mice to minimize initial A deposition. hAPP mice (n affected by AD.
12) at 4.5 months of age were administered 60 day-
release biopolymer pellets containing 13 mg of CP-Results
113,818 (7.2 mg/kg/day), while age-matched animals
were implanted with placebo pellets (n  12). RecentCP-113,818 is a fatty acid anilide derivative designed to
reports have shown that female mice have higher levelsmimic the acyl-CoA substrate of ACAT and a potent
of A and amyloid pathology than age-matched malesACAT inhibitor in vitro, cell culture, and animals (Chang
in a variety of AD transgenic mouse models (Callahanet al., 2000; Marzetta et al., 1994; Puglielli et al., 2001).
et al., 2001; Lee et al., 2002; Wang et al., 2003) andIn order to determine the in vivo efficacy of CP-113,818
that lovastatin may function in a gender-specific mannerin reducing mouse brain cholesteryl-ester levels, we ini-
(Park et al., 2003). Therefore, we included similar num-tially treated nontransgenic animals with the ACAT inhib-
bers of male and female animals in both placebo anditor. Most ACAT inhibitors are poorly absorbed when
CP-113,818 groups to detect possible gender-specificadministered orally and are quickly turned over in the
effects of the inhibitor in our mouse model. Following 4blood or tissues (Marzetta et al., 1994). To minimize
days of Morris water maze (MWM) tests, the animalsdaily fluctuations in serum CP-113,818 levels in mice,
were sacrificed at day 57 to ensure continued presencewe delivered the inhibitor via implantable slow-release
of the inhibitor. At 7.2 mg/kg/day of CP-113,818, therebiopolymer pellets. Pellets containing CP-113,818 were
was no histologic evidence of toxicity found in adrenalinserted surgically under dorsal skin to allow for continu-
cortical cells, a potential class-related effect of ACATous and controlled release of the active compound over
inhibitors (Figure 1B). Serum total cholesterol and liveran established period of time with effectively zero-order
free cholesterol/cholesteryl-esters were reduced to lev-kinetics (Innovative Research of America). Eighteen non-
els similar to those previously observed in nontrans-transgenic mice at 3 months of age received 21 day-
genic animals (Figures 1A and 1C). It is noteworthy thatrelease biopolymer pellets containing 0, 0.2, 1.6, 3.2,
liver cholesteryl-ester levels decreased by 87% (p 4.8, and 7.1 mg/kg/day of CP-113,818 (n  3 per dose;
0.0001) in hAPP mice treated for 2 months with CP-Figure 1A). The highest dose that was used in these
113,818 (Figure 1C). Taken together, these experimentsstudies was far below the tolerated dose of 150 mg/kg/
demonstrated that 2 months of CP-113,818 treatmentday for rats, even allowing for relatively low bioavailabil-
effectively reduced cholesteryl-ester levels of hAPP
ity in these animals (Marzetta et al., 1994). CP-113,818
mice in the absence of adrenal toxicity. The tissue re-
(7.1 mg/kg/day) reduced total cholesterol levels by 29%
quirements for assessment of A burden in the brains
(p  0.007) in the serum, in the absence of any evident
of these animals precluded direct examination of their
effect on food consumption and body weight (Figure brain cholesteryl-ester levels.
1A; data not shown). Hepatic free cholesterol and Brain plaque load was evaluated by thioflavin S and
cholesteryl-esters were also decreased in a dose- immunohistochemical stainings (Figure 2). Thioflavin
dependent manner by up to 37% (p  0.03) and 93% S-positive plaques were barely detectable in the cortex
(p  0.0004), respectively (Figure 1A). As expected, CP- of hAPP mice at 6.5 months of age and absent in CP-
113,818 had no effect on free cholesterol levels in the 113,818-treated animals (Figure 2A). However, A staining
brain, since free cholesterol is largely immobilized in with the monoclonal antibody 6E10 revealed abundant A
myelin membranes and is not likely perturbed by ACAT deposits in placebo-treated mouse brains (Figures 2A
activity. Initial levels of cholesteryl-esters, 2.2 mg/g of and 2B). Individual differences in amyloid load reflected
brain tissue, were similar to reported values of approxi- the well-known variability in A accumulation that has
mately 3.5 mg/g of rat hippocampal tissue (Champagne been previously observed in transgenic mice, specifi-
et al., 2003) and corresponded to 8% of total brain cally at early stages of pathology (Johnson-Wood et al.,
cholesterol. We found that free cholesterol:cholesteryl- 1997; Kawarabayashi et al., 2001). Amyloid load in the
ester ratios in mouse brains were approximately 10:1 cortex of female animals was 2-fold higher than that in
but were only 3:1 in enriched neuronal primary cultures males, in agreement with previous studies in other
largely devoid of myelin (Supplemental Figure S1 at http:// mouse models of AD (Callahan et al., 2001; Lee et al.,
www.neuron.org/cgi/content/full/44/2/227/DC1). CP- 2002; Wang et al., 2003). The hippocampus, slower than
113,818 (7.1 mg/kg) decreased cholesteryl-ester levels the cortex in developing amyloid pathology in hAPP
in mouse brains by 86% (p  0.0004; Figure 1A). Thus, mice, contained significant numbers of A deposits only
these data indicate that 7.1 mg/kg/day of CP-113,818 in female but not in male animals (Figure 2B and Supple-
is effective in markedly reducing cholesteryl-ester levels mental Figure S2 at http://www.neuron.org/cgi/content/
in the brains of nontransgenic mice. full/44/2/227/DC1). In the cortices of all animals tested,
To characterize the effect of CP-113,818 treatment CP-113,818 treatment reduced plaque numbers by 88%
on AD-like pathology, we used hAPP mice that express (p  0.0000016). Importantly, when the two genders
were considered separately, plaque numbers were re-human APP751 containing the London (V717I) and Swed-
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Figure 1. CP-113,818 Reduces Cholesteryl-
Ester Levels in Mouse Brains without Induc-
ing Adrenal Toxicity
(A) Concentration-dependent inhibition of
ACAT activity in nontransgenic mice treated
for 21 days with CP-113,818. The ACAT inhib-
itor was most effective at 7.1 mg/kg/day, re-
ducing total cholesterol in the serum by 29%
and cholesteryl-ester levels in the brain and
liver by 86% and 93%, respectively, when
compared to placebo-treated animals. Free
or membrane cholesterol was decreased by
up to 37% in the liver. Data represent mean
SD, n  3 (Student’s two-tailed t test; *p 
0.05, **p  0.01, ***p  0.001).
(B) hAPP mice treated with 7.2 mg/kg/day of
CP-113,818 for 2 months did not show signs
of vacuolization in the cytoplasm of adrenal
cortical cells (lower panels), which would rep-
resent a first indication of toxicity derived
from most ACAT inhibitors.
(C) Decreased levels of serum (35%, p 
0.0003) and liver cholesterol (34%, p 
0.00009) and liver cholesteryl-esters (87%,
p  0.00001) in hAPP mice treated with 7.2
mg/kg/day of CP-113,818 for 2 months (57
days; n  6 per treatment). These determina-
tions were made on the same animals that
were also used for brain amyloid and behavior
studies. Data represent mean  SD; n  6
(Student’s two-tailed t test; ***p  0.001).
duced to an equal extent in females and males, by 89% ning and the end of CP-113,818 treatment (Figure 2A),
suggesting that the ACAT inhibitor prevents accumula-(p 0.00002) and 88% (p 0.0002), respectively (Figure
2B). Thus, CP-113,818 treatment decreased amyloid tion of newly formed plaques. Overall, these data show
that CP-113,818 treatment was highly effective in reduc-load in a gender-independent manner. Plaque burden,
as indicated by the percent of cortex covered by ing accumulation of amyloid plaques in hAPP mice and
that this effect was gender independent.plaques, was also markedly decreased in all animals (by
90%, p  0.000012). In females, the decrease was from We next used a sandwich enzyme-linked immunosor-
bent assay (ELISA) to measure A1-40 and A1-42 levels0.45 to 0.04 percent plaque load (p  0.00002), while in
males it was from 0.10 to 0.02 (p 0.00013; Supplemen- in 70% formic acid extracts from brain homogenates
(“insoluble” A) and in the initial Tris-buffered salinetal Figure S2B). As mentioned above, amyloid load in
the hippocampus of male animals was too low at this (TBS) fraction of the same homogenates (soluble A).
Similar to plaque load, A levels varied widely, as ex-age for reliable assessment of changes caused by CP-
113,818. However, the most dramatic effects of the pected in transgenic mice specifically at early stages of
pathology (Johnson-Wood et al., 1997; KawarabayashiACAT inhibitor were observed in the hippocampus of
female mice, where plaque number decreased by 99% et al., 2001). Treatment with CP-113,818 decreased A1-40
and A1-42 in the formic acid fraction to almost undetect-(p  0.000001) and plaque coverage by 97% (p 
0.000001) from 0.295 to 0.09 percent plaque load (Figure able concentrations. An overall 92% (p  0.024) de-
crease in “insoluble” A1-40 as well as 83% (p  0.032)2B and Supplemental Figure S2B). Plaque numbers in
the cortex of female animals were similar at the begin- in “insoluble” A1-42 was detected in all animals after
Neuron
230
Figure 2. CP-113,818 Treatment for 57 Days Markedly Reduces Amyloid Load in the Brains of hAPP Transgenic Mice
(A) Representative amyloid staining (using thioflavin S) and A staining (using the antibody 6E10) of female hAPP mouse cortices at 6.5 months
of age following placebo and CP-113,818 treatments. A staining of cortices at day 0 (at 4 months of age) without and, at day 57, with CP-
113,818 treatment was remarkably similar, suggesting that the ACAT inhibitor prevented formation of amyloid pathology in these mice.
(B) Quantitative analysis of brain plaque load, as assessed by number of plaques per m2 stained with the A-specific antibody 6E10. In the
hAPP animal model, the cortex is the first to develop amyloid pathology, followed by the hippocampus. Therefore, at 6.5 months of age,
males exhibit distinct AD pathology in the cortex but not in the hippocampus. CP-113,818 reduced cortical plaque number by 88%, equally
in females (89%) and males (88%). The most marked effect was observed in the hippocampus of female mice, where amyloid load was
decreased by 99%; p  0.000001.
treatment with CP-113,818, with no significant differ- 113,818 treatment, with A1-40 down by 96% (p  0.014)
and A1-42 down by 90% (p  0.014; Figure 3A). Impor-ence in the A1-42/A1-40 ratio (Figure 3A). Since brain
extracts were obtained from entire hemispheres includ- tantly, soluble A levels were also decreased in the
initial TBS fraction, with A1-42 showing a significant 34%ing cortices and hippocampi, the difference between
male and female A levels at this age was accentuated reduction (p  0.0014). This decrease was statistically
significant in both genders. Soluble A140 levels wereby the slowly developing amyloid pathology in male hip-
pocampi (see Figure 2B). When analyzed according to close to the limit of detection, but a trend toward de-
crease was observed (20%) in all animals, significantgender, only female “insoluble” A was sufficiently ele-
vated to obtain a highly significant decrease by CP- only in males (Figure 3B). Thus, three different methods
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Figure 3. CP-113,818 Treatment Reduces Levels of “Insoluble” and Soluble A1-40 and A1-42 in the Brains of hAPP Transgenic Mice
(A) Sandwich ELISAs of “insoluble” A1-40 and A1-42 in brain formic acid extracts revealed a significant decrease of both peptides in CP-
113,818-treated animals (92% and 83%, respectively). The significance was higher in females than in males, due to lower starting A levels
in brain extracts of placebo-treated males.
(B) Sandwich ELISAs of soluble A1-40 and A1-42 in TBS fractions lacking detergents revealed a decrease of both peptides in CP-113,818-
treated animals (12% and 34%, respectively), which was significant for A1-42. A1-40 levels were close to the baseline of the assay. A decrease
was observed in both male and female animals.
of detection, thioflavin S and A stainings and A ELISAs, mice. The decrease in soluble A suggests that CP-
113,818 may either reduce A generation or accelerateindependently showed that CP-113,818 treatment is
highly effective in reducing amyloid pathology in hAPP its catabolism or clearance.
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Figure 4. CP-113,818 Treatment Restores Normal Spatial Learning and Memory in Female hAPP Mice in a Morris Water Maze Test
Behavioral performance assessing spatial navigation was evaluated for each animal three times per day for 4 days, between days 54 and 57
of treatment with CP-113,818. In each Morris water maze (MWM) trial, swimming path (length in meters required to reach the platform) and
escape latency (seconds to reach the platform) were measured. The top two panels show data collected from all animals in our study,
regardless of gender. In addition to hAPP transgenic mice, we also used equal numbers of nontransgenic littermates untreated and treated
with CP-113,818 in this study. The results show only a slight impairment in MWM trials in transgenic mice when compared to nontransgenics,
thus leaving little room for improvement due to reduced amyloid accumulation by CP-113,818. The lower panels show exclusively results
obtained with female mice. Correlating with 2-fold increased amyloid load in the female relative to the male cohort, only female transgenic
animals exhibited a significant decline in performance when compared to nontransgenic littermates. Treatment with CP-113,818 improved
this performance in the female cohort (p  0.014 on day 3), so that treated hAPP transgenic animals performed similarly to nontransgenics
in both the swimming path and escape latency tests. Data represent mean  SEM; n  3 trials per animal per day; statistical differences
were calculated with the Mann-Whitney U test.
To analyze the effect of CP-113,818 treatment on cog- treated male nontransgenic animals performed better
than the placebo-treated cohort regarding swimmingnitive function of hAPP mice, we performed MWM spa-
tial learning and memory tests on the animals. Since path (p  0.04; Supplemental Figure S3 at http://www.
neuron.org/cgi/content/full/44/2/227/DC1) but not es-hAPP mice develop cognitive deficits starting at 6
months of age, the 6.5-month-old animals in our study cape latency; however, the improvement between day
1 and day 3 or 4 was identical for both groups. All hAPPwere only expected to show slight deterioration due
to A accumulation, when compared to nontransgenic mice taken together showed a trend toward acquiring
the task quickly and reaching a plateau of performancelittermates. Consistently, length of swimming path and
time latency required for finding the submerged platform on day 3 when treated with CP-113,818 (p 0.07; Figure
4). This could have been due to a ceiling effect owingrevealed only a slight disturbance in spatial learning
and memory in transgenic animals, compared to their to maximum swimming speed. Compared to placebo,
the improvement between day 1 and day 3 due to CP-littermates. Clear impairment of cognitive function due
to A accumulation was only observed in female trans- 113,818 treatment was significant (p  0.033). As ex-
pected, CP-113,818 did not induce significant changesgenic mice. In these animals, CP-113,818 treatment re-
versed the observed impairment in spatial learning (p  in synaptic density as assessed by synaptophysin im-
munoreactivity, consistent with lack of differences be-0.014; Figure 4). Compared to placebo, CP-113,818
treatment resulted in a significant improvement of learn- tween nontransgenic versus transgenic animals given
their young age (Supplemental Figure S4). Although test-ing between day 1 and day 3 (p  0.016). CP-113,818
treatment did not affect spatial performance of non- ing of more mice at an older age will be needed to further
assess the effect of decreased amyloid pathology ontransgenic female mice, consistent with lack of Adepo-
sition in these animals. Only on day 4, CP-113,818- spatial learning and memory, improved performance in
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a MWM test correlated well with the highly significant product, and its levels are indicative of changes in both
decrease of overall plaque load and A in CP-113,818- -secretase-like and -secretase activities for Notch.
treated female animals. NICD levels were statistically unchanged by CP-113,818
Our previous cell-based studies have shown that treatment, when the protein was immunoprecipitated
ACAT inhibition reduces A generation and alters APP from nontransgenic mouse brain lysates (Figure 5C).
processing by all three secretases (Puglielli et al., 2001). Similarly, levels of N-cadherin-CTF1, the product of met-
To determine whether CP-113,818 treatment modified alloprotease cleavage and a substrate for -secretase,
brain APP processing in hAPP mice, we initially resolved were unaffected by the ACAT inhibitor (Figure 5C). These
formic acid-extracted brain proteins by SDS-PAGE to data indicate that processing of at least two -secretase
detect APP and its proteolytic derivatives. Western blot substrates was not altered by CP-113,818 and that
analysis showed that formic acid-extracted full-length -secretase-like cleavages of these substrates were
APP and APP C-terminal fragments (CTFs) C83 and C99 also unaffected. BACE protein levels were also un-
were unchanged by CP-113,818. However, levels of the changed in brain lysates of CP-113,818-treated animals
secreted cleavage products of both - and -secretases (Figure 5D). One mechanism that would explain our data
(sAPP) were reduced by treatment with the ACAT inhibi- is that ACAT inhibition may result in an interaction be-
tor, albeit not nearly as dramatically as A (Supplemen- tween APP and an unknown protein, blocking access
tal Figure S5 at http://www.neuron.org/cgi/content/full/ of the three secretases to APP instead of direct inhibition
44/2/227/DC1). Inhibition of sAPP production in the ab- of each secretase. Expression of ApoE, an essential
sence of a change in CTFs was somewhat surprising and protein in both brain lipid metabolism and Adeposition/
possibly an artifact caused by formic acid extraction. clearance, was also unchanged by ACAT inhibition (Fig-
Because tissue from treated hAPP mice had been ex- ure 5D). In an effort to exclude potential direct effects
tracted with formic acid or fixed for histological studies, of CP-113,818 on - and -secretase cleavages of APP
we looked at levels of APP-CTFs in total brain lysates in the absence of changes in cholesterol metabolism, we
from the nontransgenic littermates used in the MWM performed in vitro - and -secretase assays employing
tests. Using nontransgenic animals for these experi- purified recombinant BACE1 and membrane fractions
ments also afforded an assessment of the effects of CP- isolated from Chinese hamster ovary (CHO) cells harbor-
113,818 on endogenous APP processing. CP-113,818 ing endogenous -secretase, respectively. Both BACE1
reduced liver cholesterol/cholesteryl-esters and serum and -secretase activities were unaffected by increasing
cholesterol of nontransgenic littermates similarly to the amounts of CP-113,818 in the reaction mixture (Figures
transgenic animals shown in Figure 1C (data not shown). 5E and 5F). Finally, we tested whether CP-113,818 di-
Endogenous mouse APP-CTF levels in brain lysates rectly modulates in vitro aggregation of A40 promoted
from CP-113,818-treated animals decreased by 44% by zinc or A42 (Bush et al., 1994; Jarrett et al., 1993).
when compared to placebo-treated mice (n  8; p  CP-113,818 failed to directly inhibit aggregation of A40
0.005; values normalized to APP holoprotein levels; Fig- in vitro, when promoted by zinc (p  0.56) or A42 (p 
ures 5A and 5B). We could not resolve C99 and C83 0.96) (Figure 5G). In the absence of zinc or A42, A40
from these samples due to smearing in the low molecular alone did not significantly aggregate over 4 days (p 
weight range because of high protein load (Figure 5A). 0.671). Together, these data show that APP-CTFs, total
However, we were able to specifically detect secreted sAPP, and, to a lesser extent, sAPP levels are de-
APP (sAPP), the N-terminal product of -secretase creased in the brains of CP-113,818-treated nontrans-
cleavage, in the soluble TBS fraction of the initial homog- genic mice in the absence of any apparent change in
enate. sAPP showed a trend toward decreasing (3.4%; the levels or processing of all control proteins tested.
p  0.14  not significant) in CP-113,818-treated ani- Although these data, together with decreased soluble
mals, while total sAPP, which also includes the -secre- A in hAPP mice, argue strongly that the ACAT inhibitor
tase product sAPP, was significantly reduced by 19.1%
reduces A generation, they do not exclude additional
(p  0.038; Figures 5A and 5B). A 36% decrease (p 
beneficial effects of altered cholesterol metabolism on
0.013) in the ratio between total sAPP and sAPP indi-
A aggregation, catabolism, and/or clearance.cates that inhibition of -secretase in ACAT inhibitor-
treated mice is not as pronounced as that of other ec-
Discussiontodomain-shedding proteases (e.g., BACE). We next
asked whether -secretase component levels and  ac-
Here, we have identified a highly effective antiamyloidtivity were affected by CP-113,818 in the nontransgenic
treatment in a transgenic mouse model of AD, actingbrain lysates. We did not detect significant changes in
via inhibition of the cholesterol-esterifying enzymelevels of PS1 N- and C-terminal fragments, nicastrin,
ACAT. This treatment was gender independent in ourand pen-2 (Figure 5C; 8 of 16 samples shown, as in all
mouse model. Current antiamyloid treatment approachesother figures). Nicastrin maturation was also unaffected
for AD that are based on lowering A levels can beby CP-113,818 treatment. To detect potential changes
distinguished based on their respective targets (Citron,in - and -secretase-like activities for substrates other
2002). BACE1 and -secretase are the only targets thatthan APP, we tested two -secretase substrates, Notch
directly modulate A generation, while other strategiesand N-cadherin (De Strooper et al., 1999; Marambaud
target A aggregation (e.g. small-molecule inhibitors,et al., 2003). Both proteins are also known to undergo
metal binders) and/or clearance (e.g., A immunother--secretase-like cleavages, mediated by TACE for
apy). ACAT inhibitors, along with statins, would now fitNotch and a metalloprotease for N-cadherin (Brou et
into a third class of compounds based on targets thatal., 2000; Marambaud et al., 2003). Notch intracellular
domain (NICD) represents the final -secretase cleavage indirectly modulate A generation. ACAT inhibition pro-
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Figure 5. CP-113,818 Treatment of Nontransgenic Littermates Reduces Processing of Endogenous APP but Not Notch or N-Cadherin, without
Directly Inhibiting - and -Secretase Activities or A Aggregation
(A) Representative Western blots of APP and its cleavage products from nontransgenic mouse brains after 57 days of treatment with CP-
113,818. Full-length APP (APP-FL) and its C-terminal fragments (APP-CTF) were detected in brain lysates, while total secreted APP (sAPP)
and secreted APP (sAPP-) were detected in the initial soluble TBS fraction lacking detergents. Treatment with CP-113,818 reduces the
amounts of APP-CTFs as well as total sAPP (which includes sAPP-), while sAPP- only shows a trend toward decrease.
(B) Densitometric analysis of APP fragments resolved on Western blots. APP C-terminal fragments (CTFs) were normalized to full-length APP,
whereas sAPPtotal is shown alone and also as a ratio between sAPPtotal and sAPP, to better illustrate a reduction in sAPP forms other than
sAPP, such as sAPP. Statistical significance (n  8; p  0.05) was determined by Student’s t test.
(C) Representative Western blots of -secretase complex components and substrates after treatment of nontransgenic littermates with CP-
113,818. CP-113,818 did not alter maturation of -secretase complex in vivo, as shown by unchanged glycosylation of nicastrin, or levels of
presenilin N- and C-terminal fragments (PS1-NTF and -CTF), nicastrin, or pen-2. Furthermore, levels of N-cadherin C-terminal fragment 1
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vides additional lipid-lowering benefits while being tients, or catabolism may disproportionately accelerate
A pathology and age of onset of AD (Saido, 1998).highly effective in inhibiting formation of A pathology
in the hAPP transgenic model of amyloid deposition. Similarly, FAD mutations in the presenilin genes only
increase A42 generation by approximately 1.2- to 3-foldOur previous cell-based studies indicate that ACAT
inhibition reduces cholesteryl-ester production, which and yet cause early-onset forms of the disease that can
strike from the third decade onward (Borchelt et al.,results in decreased A generation (Puglielli et al., 2001).
In those studies, two different ACAT inhibitors, CP- 1996; Citron et al., 1997; Duff et al., 1996; Holcomb et
al., 1998). Although it is tempting to attribute decreased113,818 and Dup128, lowered cholesteryl-ester produc-
tion by up to 45% (Puglielli et al., 2001). Our current A pathology in CP-113,818-treated mice to reduced
A production, we cannot exclude the possibility thatstudy reveals a more robust decrease in mouse brain
cholesteryl-ester levels, perhaps attributable to the altered brain cholesterol metabolism may also affect A
aggregation, catabolism, and/or clearance in additionslow-release biopolymer carrier, which ensured continu-
ous delivery of the inhibitor. While it is difficult to predict to APP processing. Further studies will be necessary to
evaluate these aspects of our findings.final concentrations of CP-113,818 in the brain, crossing
of the blood-brain barrier is suggested by the structure Direct comparison between the efficacy of CP-113,818
and statins (or statin-like compounds) is nearly impossibleof this ACAT inhibitor, a small fatty acid analog, and the
marked reduction in brain cholesteryl-esters relative to due to differences in animal models, methods of drug
administration, and length of treatment employed in eachserum cholesterol, by 86% and 29%, respectively. A
previous study had reported 100-fold fluctuations of CP- study. Refolo et al. (2001) and Petanceska et al. (2002)
employed a double transgenic mouse line, PSAPP, in113,818 blood levels in monkeys after oral administra-
tion of the compound (Marzetta et al., 1994). Our own which A deposition begins at 12 weeks of age (Holcomb
et al., 1998). The cholesterol-lowering drug BM15.766attempts to quantitate liver or brain CP-113,818 have
failed, consistent with fast turnover or clearance of the (250 mg/kg/day) (Refolo et al., 2001) or 30 mg/kg/day
atorvastatin (Petanceska et al., 2002) was administeredinhibitor (Marzetta et al., 1994). Although neuronal A
generation could be affected by serum cholesterol, as orally starting at 8 weeks of age and ending after 5 and
8 weeks, respectively. BM15.766 reduced amyloid loadsuggested by a number of studies correlating serum
cholesterol with brain A levels (Puglielli et al., 2003), it by 53%, formic acid-extracted A40 by 58%, and A42
by 48% (Refolo et al., 2001). Atorvastatin lowered amy-is unlikely that a 29% decrease in serum cholesterol
would reduce brain A to the levels found in the current loid load by62% (2.7-fold), with formic acid-extracted
A40 and A42 decreasing by 60 (2.5-fold) and 50%study. A more likely explanation is that altered intra-
cellular cholesterol metabolism, evidenced by the 86% (2-fold), respectively (Petanceska et al., 2002). In another
study conducted in guinea pigs, 250 mg/kg/day ofdecrease in brain cholesteryl-esters, is responsible for
the observed reduction in A accumulation in CP- orally administered simvastatin reduced endogenous
detergent-extracted total A by 45% in 3 weeks of113,818-treated animals.
In transgenic mice, soluble A42 only decreased by treatment (Fassbender et al., 2001). Interestingly, one
report has shown that lovastatin treatment of 12-month-34%, while “insoluble” A decreased by 83%–99%.
These data may be explained by the complex metabo- old Tg2576 mice (expressing FAD mutant APP) for 3 weeks
did not affect amyloid load or brain A levels in maleslism of these peptides in the brain, such that the net
amount of soluble A is the result of not only its rate while increasing A pathology in female animals (Park
et al., 2003). It is not clear whether this contrasting resultof generation alone, but also its rates of deposition,
degradation, and clearance (Saido, 1998). On the other reflects differences in genetic backgrounds or the short
treatment time beginning at a late age, after develop-hand, reduction in A generation alone could largely
account for the surprisingly robust effect of CP-113,818 ment of large A deposits. Female Tg2576 mice have
been reported to develop amyloid pathology beforeon “insoluble” A and amyloid plaques in mouse brains.
Small changes in A generation, exemplified by a 50% males, perhaps due to higher synaptic zinc content in
female brains by the age of 12 months (Callahan et al.,increase in APP gene dosage in Down’s syndrome pa-
(CTF) and Notch-1 intracellular domain (ICD) remained unchanged, suggesting that treatment with CP-113,818 does not perturb normal
functions of the -secretase complex. The asterisk indicates an aspecific band.
(D) Representative Western blots of BACE1 and ApoE after treatment of nontransgenic littermates with CP-113,818. Treatment with CP-
113,818 did not alter expression levels of BACE1 in brain lysates or ApoE in the soluble TBS fraction.
(E) In vitro fluorometric BACE1 activity assay performed with purified recombinant human BACE1 in the presence of increasing amounts of
CP-113,818. While GL-189, a specific -secretase inhibitor, significantly reduces BACE1 activity, CP-113,818 has no direct effect on BACE1
activity in vitro.
(F) In vitro -secretase activity assay performed on CHO cell (overexpressing APP) membrane fractions in the presence of increasing amounts
of CP-113,818. While L-685,458, a specific -secretase inhibitor, inhibits APP intracellular domain (AICD) generation, CP-113,818 has no direct
effect on -secretase activity in vitro. C99 and C83, APP C-terminal fragments.
(G) In vitro aggregation assay testing the effect of CP-113,818 on metal- or A42-mediated aggregation of A40. A40 was incubated alone or
with “aged” A42 or Zn2	 with or without 10 M CP-113,818 in the wells of a 384-well microassay plate. Sample turbidity was monitored by
following well absorbance at 400 nm over 4 days. Test signal was blanked on wells containing no A40. CP-113,818 does not directly modulate
metal- or A42-mediated aggregation of A40 in vitro. Aggregation of A40 alone was not significant (p  0.671 between time 0 and 4 days).
Data points are shown as average of eight replicates  standard error. Significance values were calculated using Student’s t test (two-tailed).
(Gray solid square, A40; black unfilled triangle, A40 	 CP-113,818; gray solid triangle, A40 	 A42; black unfilled circle, A40 	 A42 	 CP-
113,818; gray solid circle, A40 	 Zn; black unfilled square, A40 	 Zn 	 CP-113,818.)
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Cholesterol Determinations2001; Lee et al., 2002). Although difficult to compare in
Tissues were homogenized in the presence of trypsin (10 mg/ml) inefficacy to CP-113,818, it is clear that statins or statin-
a Dounce homogenizer on ice. Protein concentration of the homoge-like drugs strongly reduce A pathology in different ani-
nate was determined using the BCA protein assay kit (Pierce). The
mal models when administered prior to A deposition. tissue homogenate was extracted in chloroform:methanol (2:1, v/v)
It can be speculated that the influence of ACAT inhibition overnight. Before drying the chloroform phase, polyoxyethylene-9-
lauryl ether (Sigma; 5 l/ml of extract) was added. Dried lipid pelletson APP metabolism is additive to effects resulting from
were dissolved in water, and total amount of cholesterol was deter-changes in total cholesterol levels. Thus, in principle
mined with an enzymatic assay (Sigma; cat. no. 402–20). As control,statins and ACAT inhibitors together could exhibit syn-
free cholesterol was determined with a different enzymatic assayergy in positively impacting AD pathology in patients
(R-Biopharm GmbH, Darmstadt, Germany; cat. no. E0139050). The
affected by the disease. amount of cholesteryl-esters was calculated by subtracting free
CP-113,818 has never been tested in clinical trials, from total cholesterol. Finally, the values were normalized to protein
concentration of the tissue homogenate and expressed in mg ofwhile CI-1011 (avasimibe), a well-studied ACAT inhibitor
cholesterol per g of protein.produced by Pfizer, previously entered phase III trials
for vascular disease and atherosclerosis. Avasimibe is
Brain Plaque Load and Synaptophysin Analysesconsidered safe for human use, with a good therapeutic
For histomorphological analyses, 8 to 15 histological sections (10window. Our results suggest that slow-release biopoly-
m) were prepared from one hemisphere of 12 animals (six placebo,
mer administration of ACAT inhibitors may be consid- six CP-113,818; three male, three female per group). Number and
ered as a potential strategy for the treatment and pre- surface area of amyloid plaques were evaluated in both cortex and
hippocampus. 6E10 (Signet; 1:5000; monoclonal) as primary anti-vention of Alzheimer’s disease, alone or in combination
body and Cy3 fluorescent goat anti-mouse IgG as secondary anti-with statins.
body (Jackson ImmunoResearch) were used for A staining. Sec-
tions of the same brains were also used for synaptophysin stainingExperimental Procedures
(Chemicon; 1:5000; monoclonal). Synaptophysin immunoreactive
spots were counted by light microscopy in the hippocampal CA1Animals and Drug Treatment
region. The estimation of immunohistochemical reactions was donehAPP transgenic mice overexpress human APP751 with the London
by computer-assisted quantification (Image-Pro Plus, Media Cyber-(V717I) and Swedish (K670M/N671L) mutations under the regulatory
netics).control of the neuron-specific murine (m)Thy-1 promoter (mThy-1-
hAPP751; heterozygous with respect to the transgene, on a C57BL/6
A1-40 and A1-42 DeterminationsF3 background) (Rockenstein et al., 2001). The hAPP colony was
For A determinations, frozen hemispheres were first homogenizedsustained by crossing transgenic APP751 with C57BL/6 (Harlan Win-
in TBS buffer (5 ml) containing a protease inhibitor cocktail (Proteasekelmann, Germany). Corresponding littermates were used for con-
Inhibitor Cocktail Set I, Calbiochem) and then centrifuged at 75,000 gtrol studies. All mice were housed according to standard animal care
for 1 hr, as described elsewhere (Kawarabayashi et al., 2001). Super-protocols, fed ad libitum with standard chow diet, and maintained in
natants were saved for soluble A analyses (see below). Pelletsa pathogen-free environment in single ventilated cages at JSW-
were resuspended and further homogenized in 70% formic acid (1Research. The transgenic status of each animal was confirmed by
ml), followed by centrifugation at 75,000 g for 1 hr. Formic acidreal-time PCR of tail snips using specific primers and the appropriate
supernatants were neutralized with 1 M Tris (19 ml) and used forhybridization probe. A modified Irvine test was regularly performed
ELISA determination (insoluble A). A1-40 and A1-42 were assayedprior to the experiment to assess the neurological status of the
using commercially available ELISA kits (The Genetics Company,animals; those showing disturbances were excluded from the exper-
Switzerland). Measurements were performed at least in duplicate.iments. Mice were then randomly assigned to different treatment
For soluble A ELISAs, secreted A1-40 and A1-42 levels in the TBSgroups and individually coded. Investigators performing behavioral
homogenate were analyzed by a sandwich ELISA system as de-testing, biochemical analyses, and histomorphological evaluations
scribed previously using the following antibodies: A40  MM27of the brains were blinded in terms of group allocation of the mice.
33.1.1 capture, MM32 13.1.1 for detection; A42  MM27 33.1.1CP-113,818, a potent inhibitor of both ACAT1 and ACAT2 (Chang
capture, MM26 4.1.3 for detection (Suzuki et al., 1994).et al., 2000), was graciously provided by Dr. James Harwood (Pfizer,
Groton, CT). The drug was compounded in release pellets for contin-
uous dosing by Innovative Research of America (Sarasota, FL). Only Behavior
Fifty-three days after the treatment, mice were trained in the MWMthe test compound, but not carrier biopolymers and substances in
the pellets, was released into the bloodstream. Pellets were gener- spatial navigation task, in which a mouse swims to find a hidden
platform, using visual cues. The task is based on the principle thatated to provide either 21 days or 60 days of continuous drug delivery.
For implantation of pellets, animals were anesthetized with isoflur- rodents are highly motivated to escape from a water environment
by the quickest, most direct route. This task is carried out in aane. Then, sterile pellets containing either CP-113,818 or placebo
were implanted subcutaneously along the anterolateral aspect of circular pool (1 m diameter) filled with water (22
C 1
C) and virtually
divided into four quadrants. A platform is placed in the southwestthe left shoulder with a special precision trocar in accordance with
the supplier’s instructions. There was no evident need for additional quadrant 1 cm beneath the surface of the water. The computer
randomly changes the starting positions of an animal. On 4 consecu-hemostasis, and no signs of infection, discomfort, or distress were
observed in association with the implantation and treatment. tive days, mice attend three trials per day (each lasting for a maxi-
mum of 60 s). Escape latency (time to find the hidden platform) and
length of swimming path were measured. Significant differences ofTissue Sampling
the behavioral results were calculated with the Mann-Whitney U test.Animals were sacrificed the day after the last MWM training, on day
57 of treatment. Blood was obtained by cardiac puncture, and total
serum was used for cholesterol determination. Transcardiac perfu- Western Blot Analysis
For Western blot analyses, frozen hemispheres of nontransgenicsion with 4C PBS was performed, followed by dissection. Brains
were removed, divided along the sagittal plane, and then either littermates were homogenized in TBS buffer containing 5 mM EDTA,
1 mM 1,10-phenanthroline (ICN Biomedicals), 20 M ALLN (BioMol),frozen in liquid nitrogen or immersion fixed with 4% paraformalde-
hyde for histologic evaluation. Liver was frozen in liquid nitrogen, and a protease inhibitor mixture (Roche). Homogenates were centri-
fuged at 100,000 g for 1 hr at 	4
C. The supernatants were usedand adrenal glands were fixed in 4% paraformaldehyde followed
by standard paraffin embedding and sectioning. Hematoxylin and for analyses of secreted APP forms and ApoE, while the pellets
were extracted with the homogenization buffer containing 1% Tritoneosin-stained 6–8 m sections were analyzed for evidence of CP-
113,818 toxicity. X-100 and 0.2% SDS. Total protein (120 g) was resolved on 4%–
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12% or 12% NuPAGE Bis-Tris gels (Invitrogen) under reducing con- pen-2 antibody; Samuel E. Gandy (Thomas Jefferson University,
Philadelphia, PA) for the Ab14 antibody; David M. Holtzman (Wash-ditions, and Western blots were performed as described previously
(Puglielli et al., 2001). For analysis of NICD, 250 g of total protein ington University School of Medicine, St. Louis, MO) for his kind
suggestions for detecting brain ApoE; and Rudolph E. Tanzi (Massa-was immunoprecipitated with an NICD-specific antibody (cleavage
site [Val1744]-specific; Cell Signaling Technology) according to the chusetts General Hospital, Boston, MA) for his useful comments
in the preparation and editing of this manuscript. This work wasmanufacturer’s recommendations. Antibodies used for Western
blots were R1736 (specific for sAPP-; a gift from Dr. D.J. Selkoe, supported by the Institute for the Study of Aging (ISOA; D.M.K.); the
NIH/NINDS (D.M.K.); and the Alzheimer’s Association (L.P.). M.P.F.Brigham and Women’s Hospital, Boston, MA), Ab14 (PS1-NTF; a
gift from Dr. S.E. Gandy, Thomas Jefferson University, Philadelphia, is partially supported as a Paul Beeson Physician Faculty Scholar
in Aging Research.PA), pen-2 (a gift from Dr. S.S. Sisodia, University of Chicago, Chi-
cago, IL), N-Cadherin (C32, C-terminal; BD Transduction Labora-
tories), ApoE (Santa Cruz Biotechnology), -tubulin (Sigma), BACE1, Received: February 19, 2004
and Nicastrin (Affinity BioReagents). Rbt  APP (CTF), 22C11 (APP- Revised: July 28, 2004
NTF), and Rbt  PS1 (PS1-CTF) were from Chemicon International. Accepted: August 17, 2004
BACE stainings (N-terminal; Affinity BioReagents) were confirmed Published: October 13, 2004
with two additional antibodies; Ms  BACE1 (Chemicon Interna-
tional) and BACE (C-terminal; Affinity BioReagents). Densitometric References
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